Who holds the nusinersen (Spinraza) patents?
Biogen (with partners involved in development and commercialization) is the key company associated with nusinersen, which is marketed as Spinraza for spinal muscular atrophy (SMA) [1]. Patent rights for nusinersen are enforced through national and regional patents and are split across jurisdictions, so “the” patent expiry depends on the country you mean [1].
When does the nusinersen patent expire?
You can’t give a single global expiry date because nusinersen is covered by multiple patent families and those terms vary by country and filing dates [1]. The practical way to determine the date for your jurisdiction is to check the specific patents that cover:
- the core drug substance/composition
- the specific formulation/delivery
- manufacturing processes
- method-of-use claims (indications/dosing)
What else can delay market entry besides patent expiry?
Even after a patent’s term ends, marketing can be delayed by other kinds of exclusivity and by additional patents in related families. For nusinersen, the time-to-entry for competitors is tied to the full patent “estate” across territories, not just one document [1].
Are there biosimilars or generics of nusinersen?
The question of biosimilar or follow-on availability depends on how regulators classify and approve nusinersen-like products and on which patents remain in force in each country. Because patent coverage differs by jurisdiction and can include method-of-use claims, the ability for a competitor to launch is typically constrained until relevant rights expire or are cleared [1].
Why do patent dates vary so much between countries?
Patent term usually depends on the jurisdiction’s rules (including term adjustments and extensions where available) plus the filing history of each patent family. For nusinersen, that means different countries can have different end dates for different claims, even when the drug was developed by the same company [1].
Where can I check the exact nusinersen patent status for a specific country?
Use a national patent database (or a global patent portal that indexes multiple jurisdictions) and search for nusinersen/Spinraza assignees and key patent family documents, then filter by:
- assignee (e.g., Biogen)
- jurisdiction/country
- current legal status
- expiry/termination dates
If you tell me the country (for example, US, EU/UK, Japan, Canada, etc.), I can narrow the answer to what matters for that market.
Sources:
[1] Biogen - Spinraza (nusinersen) information page (company/marketed product context). https://www.biogen.com/en_us/pipeline/spinraza.html